Alimta (Pemetrexed) Chemotherapy Treatment

News Alert: FDA Approves Alimta

"Patients on the new chemotherapy drug (brand name Alimta) live longer and have less pain than those on other drug treatments".

Research results were announced at the annual meeting of the American Society of Clinical Oncology.

Learn more about Alimta >>

In July 2002, The FDA and Eli Lilly Company announced that Alimta (pemetrexed) would be available to patients with malignant mesothelioma. The drug, is not yet fully FDA approved, but is available to "qualified patients who have been diagnosed with malignant pleural mesothelioma and have not yet received treatment." The FDA allows Alimta to be used under "Expanded Access Program," that allows new treatments available to patients with diseases like mesothelioma where treatment options are limited. Under the program, patients with mesothelioma can get Alimta during the FDA review process.

If you or someone you know has been diagnosed with malignant mesothelioma you may have unpaid medical expenses and be unaware of your rights.

We invite you to contact us to discuss your options to help pay for treatment.

Get Financial + Legal | What is Malignant Mesothelioma? | Alimta (Pemetrexed) Treatment
Other Treatment Options | Clinical Trials | Paying for Treatment | Home

All Contents Copyright, 2008 Alimta (Pemetrexed) Treatment Center

This site is not owned or operated by Eli Lilly.
Alimta is a Trademark of Eli Lilly.

Terms and Conditions